OR13D1: A Potential Drug Target and Biomarker for Ovarian Cancer
OR13D1: A Potential Drug Target and Biomarker for Ovarian Cancer
Ovarian cancer is a leading cause of cancer death in women, with estimates suggesting that in the United States, over 21,000 women will be diagnosed with ovarian cancer this year. Despite advances in treatment, the survival rate for ovarian cancer remains largely the same, with a five-year survival rate of only 40%. Therefore, there is a significant need for new and more effective treatments for ovarian cancer.
One potential drug target for ovarian cancer is OR13D1, a G protein-coupled receptor (GPCR) located on the surface of ovarian cancer cells. OR13D1 is involved in a variety of cellular processes that are relevant to the development and progression of ovarian cancer, including cell survival, angiogenesis, and chemotherapy resistance. Therefore, targeting OR13D1 with drugs or other therapeutic agents has the potential to be a valuable new treatment option for ovarian cancer.
OR13D1 functions as a GPCR, which is a type of protein receptor that plays a critical role in cellular signaling. GPCRs are involved in many different cellular processes, including sensory perception, neurotransmission, and hormone signaling. In the context of ovarian cancer, OR13D1 is involved in a variety of cellular processes that are relevant to cancer progression, including the regulation of cell survival, angiogenesis, and chemotherapy resistance.
One of the key functions of OR13D1 is its role in cell survival. Ovarian cancer cells have a unique ability to evade the effects of chemotherapy and other forms of treatment, which allows them to maintain a high survival rate. OR13D1 is involved in this process by regulating the ability of cancer cells to divide and survive in the face of chemotherapy. By targeting OR13D1 with drugs or other therapeutic agents, it may be possible to disrupt these cancer cells' ability to survive and promote their death.
OR13D1 is also involved in the process of angiogenesis, which is the formation of new blood vessels that feed the growing tumor. In ovarian cancer, angiogenesis is a key factor in tumor growth and progression. By targeting OR13D1 with drugs or other therapeutic agents, it may be possible to disrupt the formation of new blood vessels and inhibit the growth of the tumor.
In addition to its role in cell survival and angiogenesis, OR13D1 is also involved in the regulation of chemotherapy resistance. Ovarian cancer cells often have multiple copies of OR13D1, which allows them to resist the effects of chemotherapy. By targeting OR13D1 with drugs or other therapeutic agents, it may be possible to disrupt the multiplication of OR13D1 and inhibit the cancer cells' resistance to chemotherapy.
The development and testing of new treatments for ovarian cancer can be a complex and challenging process. OR13D1 is an attractive drug target because it is involved in a variety of cellular processes that are relevant to cancer progression, and it may be possible to disrupt these processes with new therapeutic agents. However, the development of new treatments for ovarian cancer is a complex process that requires a combination of basic research, preclinical studies, and clinical trials.
In conclusion, OR13D1 is a potential drug target and biomarker for ovarian cancer. Its role in cell survival, angiogenesis, and chemotherapy resistance makes it an attractive target for new therapeutic agents. Further research is needed to develop and test new treatments for ovarian cancer that target OR13D1.
Protein Name: Olfactory Receptor Family 13 Subfamily D Member 1
Functions: Odorant receptor
The "OR13D1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR13D1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1 | OR1Q1 | OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14 | OR2A2 | OR2A20P | OR2A25 | OR2A4 | OR2A42 | OR2A7 | OR2A9P | OR2AE1 | OR2AG1 | OR2AG2 | OR2AJ1 | OR2AK2 | OR2AL1P | OR2AM1P | OR2AP1 | OR2AT4 | OR2B11 | OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11
